Diagnosis suspected at baseline for patients with (group A1) or without (group A2) follow-up visit in our clinic
| N=331 | RA (n=83) | Spondylarthropathy (n=74) | CTD (n=52) | FMS/CSS (n=2) | Osteoarthritis (n=26) | ‘Other inflammatory’ (n=32) | ‘Other non-inflammatory’ (n=61) | No diagnosis (n=1) |
|---|---|---|---|---|---|---|---|---|
| Group A1 (n (%)) (follow-up in the clinic) | 61 (28.6) | 51 (23.9) | 43 (20.2) | 1 (0.5) | 16 (7.5) | 14 (6.6) | 27 (12.7) | 0 |
| Group A2 (n (%)) (stopped clinic attendance) | 22 (18.6) | 23 (19.5) | 9 (7.6) | 1 (0.8) | 10 (8.5) | 18 (15.3) | 34 (28.8) | 1 (0.8) |
In the patients initially assigned to follow-up in the outpatient clinic (group A), and who were followed for 6–12 months, distribution of diagnoses suspected at baseline differed significantly between groups A1 and A2 (p<0.0001; χ2 test).
CSS, central sensitivity syndrome; CTD, connective tissue disease; FMS, fibromyalgia syndrome; RA, rheumatoid arthritis.